Raymond James & Associates Nuvalent, Inc. Transaction History
Raymond James & Associates
- $161 Billion
- Q3 2024
A detailed history of Raymond James & Associates transactions in Nuvalent, Inc. stock. As of the latest transaction made, Raymond James & Associates holds 8,661 shares of NUVL stock, worth $814,913. This represents 0.0% of its overall portfolio holdings.
Number of Shares
8,661
Previous 4,641
86.62%
Holding current value
$814,913
Previous $352,000
151.7%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding NUVL
# of Institutions
177Shares Held
56.6MCall Options Held
527KPut Options Held
131K-
Deerfield Management Company, L.P. (Series C) New York, NY20MShares$1.88 Billion31.83% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY4.57MShares$430 Million14.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.78MShares$355 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.02MShares$284 Million0.01% of portfolio
-
Bain Capital Life Sciences Investors, LLC Boston, MA2.7MShares$254 Million41.86% of portfolio
About Nuvalent, Inc.
- Ticker NUVL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 42,977,800
- Market Cap $4.04B
- Description
- Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...